Performance of spleen stiffness measurement to rule out high-risk varices in patients with porto-sinusoidal vascular disorder
- PMID: 38954825
- DOI: 10.1097/HEP.0000000000001004
Performance of spleen stiffness measurement to rule out high-risk varices in patients with porto-sinusoidal vascular disorder
Abstract
Background and aims: Baveno VII consensus suggests that screening endoscopy can be spared in patients with compensated cirrhosis when spleen stiffness measurement (SSM) by vibration-controlled transient elastography (VCTE) is ≤40 kPa as they have a low probability of high-risk varices (HRV). Conversely, screening endoscopy is required in all patients with porto-sinusoidal vascular disorder (PSVD). This study aimed to evaluate the performance of SSM-VCTE to rule out HRV in patients with PSVD and signs of portal hypertension.
Approach and results: We retrospectively included patients with PSVD, ≥1 sign of portal hypertension, without a history of variceal bleeding, who underwent an SSM-VCTE within 2 years before or after an upper endoscopy in 21 VALDIG centers, divided into a derivation and a validation cohort. One hundred fifty-four patients were included in the derivation cohort; 43% had HRV. By multivariable logistic regression analysis, SSM-VCTE >40 kPa and serum bilirubin ≥1 mg/dL were associated with HRV. SSM-VCTE ≤40 kPa combined with bilirubin <1 mg/dL had a sensitivity of 96% to rule out HRV and could spare 38% of screening endoscopies, with 4% of HRV missed, and a 95% negative predictive value. In the validation cohort, including 155 patients, SSM combined with bilirubin could spare 21% of screening endoscopies, with 4% of HRV missed and a 94% negative predictive value.
Conclusions: This study gathering a total of 309 patients with PSVD showed that SSM-VCTE ≤40 kPa combined with bilirubin <1 mg/dL identifies patients with PSVD and portal hypertension with a probability of HRV <5%, in whom screening endoscopy can be spared.
Copyright © 2024 American Association for the Study of Liver Diseases.
References
-
- De Gottardi A, Rautou PE, Schouten J, Rubbia-Brandt L, Leebeek F, Trebicka J, et al. Porto-sinusoidal vascular disease: Proposal and description of a novel entity. Lancet Gastroenterol Hepatol. 2019;4:399–411.
-
- De Gottardi A, Sempoux C, Berzigotti A. Porto-sinusoidal vascular disorder. J Hepatol. 2022;77:1124–1135.
-
- Wöran K, Semmler G, Jachs M, Simbrunner B, Bauer DJM, Binter T, et al. Clinical course of porto-sinusoidal vascular disease is distinct from idiopathic noncirrhotic portal hypertension. Clin Gastroenterol Hepatol. 2022;20:e251–e266.
-
- Abraldes JG, Bureau C, Stefanescu H, Augustin S, Ney M, Blasco H, et al. Noninvasive tools and risk of clinically significant portal hypertension and varices in compensated cirrhosis: The “Anticipate” study. Hepatol Baltim Md. 2016;64:2173–2184.
-
- Kumar A, Maruyama H, Arora A, Sharma P, Anikhindi SA, Bansal N, et al. Diagnostic accuracy of transient elastography in diagnosing clinically significant portal hypertension in patients with chronic liver disease: A systematic review and meta-analysis. J Med Ultrason 2001. 2022;49:333–346.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources